Our new ThinkLive Commercialization event dedicated to topics that impact market access and commercialization strategy took place in early February 2021. Our brand new ABLive platform will enable on-demand access to the event through May, including the chance to meet one-one-one with the AmerisourceBergen team. Below are highlights and additional resources from the event.
Innovation
How to make the most of integrated commercialization solutions
For pharmaceutical companies, bringing a new therapy to market can be a long and expensive journey. Research and development alone can cost $2.6 billion, on average, and can take several years. Yet, developing a quality product and getting it approved for distribution is not enough to guarantee commercial success.
Speeding access to therapy with pharmacy eBV
As the payer landscape grows increasingly complex, manufacturers have to navigate new requirements at every juncture of the drug commercialization process. How manufacturers handle the intricate healthcare landscape could impact if and when patients can access the therapies they need.
Emerging Therapies
Cell and gene therapies: bringing innovation to market
With the potential of 40+ groundbreaking cell and gene therapy products FDA-approved by 2024, manufacturers are looking for innovative ways to successfully bring these therapies to market.
Join AmerisourceBergen experts for a webinar as they discuss commercialization considerations that manufacturers should know.
Considerations for the commercialization of cell and gene therapies
What should cell and gene therapies manufacturers know about bringing these innovative treatments to market?
Join AmerisourceBergen experts for a recorded panel discussion that include an overview of what cell and gene therapies are, the end-to-end product and financial flow, the patient support model for these groundbreaking therapies, and considerations for reimbursement, ordering, logistics, and more.
Biosimilars Pipeline Report: A guide for understanding the growing market
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.
COVID-19 Implications
Patient Experience
Rethink field services: Three myths keeping access barriers in front of your product
The current myths that may have the biggest impact on your product should you continue to believe them:
- Myth #1: I only need field services for buy-and-bill products
- Myth #2: Field services are only impactful in person
- Myth #3: Field services aren't designed for small pharma
Case study: an innovative field reimbursement program expands patient access
Learn how Xcenda designed and launched a best-in-class field reimbursement and access support program. Steps include:
- Make informed decisions
- Knowledgeable experts and useful tools
- Data-driven solutions
- Convenient access to online education
Patient support launch guide: competitive markets
Everything you need to know about utilizing patient support programs to launch your product in a competitive marketplace. You'll learn:
- How to leverage a proven program launch framework
- Key considerations for differentiating your new therapy in a competitive market
- Best practices for building and implementing a patient-centric support program
- Questions to ask when selecting a patient support partner for your new therapy
Patient support launch guide: novel therapies
Get actionable insights from Lash Group experts to help you learn how to ensure patient support success as an innovator in a therapeutic area. You’ll learn:
- How to leverage a proven program launch framework and key considerations at each phase
- The right resources to dedicate to your program launch
- The factors that can impact your launch timeline
- The questions to ask when selecting a patient support partner for your novel therapy
Data & Analytics
Global Markets
In The News
Meeting the commercialization challenge of a surging cell and gene therapy market
Undaunted by the challenges the COVID-19 pandemic unleashed on the world the expected surge of cell and gene therapies already in the pipeline and on the horizon will continue to materialize, and with them the complexity of riding that wave of innovation.
Speeding past patient access barriers to deliver therapies in a post-pandemic world
As economies open up and jobs begin to return, pharmaceutical manufacturers continue to work closely with patient support providers and field solutions teams to overcome the challenges COVID-19 imposed and identify which digital tools will help eliminate provider and patient access barriers—both now and in the future.
Meeting the challenge to deliver COVID-19 relief around the world
Delivering COVID-19 vaccines worldwide requires a coordinated ballet of supply chain partners and stakeholders ranging from airport handlers, ground transportation crews and security officials who must coordinate with, depending on the country, local, state, provincial and government law enforcement agencies. All of that amidst a backdrop of ongoing lockdowns and transport restrictions.
Commercialization in Canada: Navigating Complex Requirements to Drive Product Success
The Canadian pharmaceutical market, which is among the 10 largest worldwide, has long been viewed as a top-tier launch destination. However, the path to product commercialization in Canada is complex and can be challenging.
Addressing Disparities in Access: Designing Patient Support Programs to Close Gaps, Improve Health Outcomes
Recent research shows the COVID-19 pandemic has exacerbated racial and socioeconomic disparities in access to healthcare and health insurance. Patient support programs are designed to remove barriers to care and help patients access, afford and remain on the treatment they need.
Cell and gene therapy: Creating connections amid complexity
Product developments in cell and gene therapy are both among the most groundbreaking and the most complex. Cell and gene therapy product launch success hinges on investment in the right technology and data solutions, and that also means finding the right partner.